SAB Biotherapeutics (SABS) Payables (2020 - 2025)
Historic Payables for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $6.9 million.
- SAB Biotherapeutics' Payables fell 43.22% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $5.7 million for FY2024, which is 2575.41% down from last year.
- As of Q3 2025, SAB Biotherapeutics' Payables stood at $6.9 million, which was down 43.22% from $7.1 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Payables registered a high of $14.3 million during Q4 2021, and its lowest value of $5.7 million during Q2 2024.
- Its 5-year average for Payables is $8.2 million, with a median of $7.0 million in 2024.
- As far as peak fluctuations go, SAB Biotherapeutics' Payables skyrocketed by 7610.76% in 2021, and later crashed by 4307.75% in 2023.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Payables stood at $14.3 million in 2021, then dropped by 24.99% to $10.7 million in 2022, then fell by 27.57% to $7.7 million in 2023, then decreased by 25.75% to $5.7 million in 2024, then increased by 19.15% to $6.9 million in 2025.
- Its Payables was $6.9 million in Q3 2025, compared to $7.1 million in Q2 2025 and $6.2 million in Q1 2025.